206 related articles for article (PubMed ID: 36394590)
1. [Melanoma-associated macrophages-from molecular signals to therapeutic application].
Chatziioannou E; Aydin SA; Forchhammer S; Sinnberg T; Eigentler T
Dermatologie (Heidelb); 2022 Dec; 73(12):915-928. PubMed ID: 36394590
[TBL] [Abstract][Full Text] [Related]
2. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
3. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
[TBL] [Abstract][Full Text] [Related]
4. Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer.
Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
Eur J Pharm Sci; 2023 Jun; 185():106427. PubMed ID: 36948408
[TBL] [Abstract][Full Text] [Related]
5. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
6. TFEB is a master regulator of tumor-associated macrophages in breast cancer.
Li Y; Hodge J; Liu Q; Wang J; Wang Y; Evans TD; Altomare D; Yao Y; Murphy EA; Razani B; Fan D
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487570
[TBL] [Abstract][Full Text] [Related]
7. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary administration of a CSF-1R inhibitor alters the balance of tumor-associated macrophages and supports first-line chemotherapy in a lung cancer model.
Zhang H; Almuqbil RM; Alhudaithi SS; Sunbul FS; da Rocha SRP
Int J Pharm; 2021 Apr; 598():120350. PubMed ID: 33545279
[TBL] [Abstract][Full Text] [Related]
9. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for Prostate Cancer Therapy.
Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
Mol Pharm; 2023 Nov; 20(11):5921-5936. PubMed ID: 37874541
[TBL] [Abstract][Full Text] [Related]
10. The role of tumor-associated macrophage in breast cancer biology.
Choi J; Gyamfi J; Jang H; Koo JS
Histol Histopathol; 2018 Feb; 33(2):133-145. PubMed ID: 28681373
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
[TBL] [Abstract][Full Text] [Related]
12. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
13. Clotrimazole presents anticancer properties against a mouse melanoma model acting as a PI3K inhibitor and inducing repolarization of tumor-associated macrophages.
Ochioni AC; Imbroisi Filho R; Esteves AM; Leandro JGB; Demaria TM; do Nascimento Júnior JX; Pereira-Dutra FS; Bozza PT; Sola-Penna M; Zancan P
Biochim Biophys Acta Mol Basis Dis; 2021 Dec; 1867(12):166263. PubMed ID: 34481868
[TBL] [Abstract][Full Text] [Related]
14. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
Hofman L; Lawler SE; Lamfers MLM
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
[TBL] [Abstract][Full Text] [Related]
15. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
Chesney J; Imbert-Fernandez Y; Telang S; Baum M; Ranjan S; Fraig M; Batty N
Melanoma Res; 2018 Jun; 28(3):250-255. PubMed ID: 29561296
[TBL] [Abstract][Full Text] [Related]
16. Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.
Evrard D; Szturz P; Tijeras-Raballand A; Astorgues-Xerri L; Abitbol C; Paradis V; Raymond E; Albert S; Barry B; Faivre S
Oral Oncol; 2019 Jan; 88():29-38. PubMed ID: 30616794
[TBL] [Abstract][Full Text] [Related]
17. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
Dummer R; Hoeller C; Gruter IP; Michielin O
Cancer Immunol Immunother; 2017 Jun; 66(6):683-695. PubMed ID: 28238174
[TBL] [Abstract][Full Text] [Related]
18. The role of macrophage in regulating tumour microenvironment and the strategies for reprogramming tumour-associated macrophages in antitumour therapy.
Xu L; Xie X; Luo Y
Eur J Cell Biol; 2021 Mar; 100(2):151153. PubMed ID: 33476912
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system.
Nam SJ; Kim S; Kwon D; Kim H; Kim S; Lee E; Kim TM; Heo DS; Park SH; Lim MS; Kim CW; Jeon YK
Oncoimmunology; 2018; 7(7):e1442164. PubMed ID: 29900049
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumor-associated macrophages for cancer immunotherapy.
Cao X; Lai SWT; Chen S; Wang S; Feng M
Int Rev Cell Mol Biol; 2022; 368():61-108. PubMed ID: 35636930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]